NovaBridge Biosciences (NBP) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 38.0% versus a loss of 80.4%. Over five years, UNCY leads with a -88.5% price change compared with -98.7% for NBP. Unicycive Therapeutics is the larger company by market cap ($97.8 million vs $96.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBP | UNCY |
|---|---|---|
| Share price | $0.83 | $3.35 |
| Market cap | $96.28M | $97.77M |
| 1-day change | -5.66% | -5.10% |
| YTD return | -79.15% | -41.94% |
| 1-year return | -80.38% | -37.96% |
| 5-year return | -98.69% | -88.53% |
| Forward P/E | — | 4.86 |
| EPS (TTM) | $-0.69 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-46.27M | $-26.55M |
| 52-week high | $5.19 | $8.74 |
| 52-week low | $0.751 | $3.33 |
| Distance from 52-week high | -84.01% | -61.67% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +944.58% | +685.07% |
| Average volume | 515.66K | 963.80K |
| Shares outstanding | 116.00M | 29.18M |
| Employees | 30 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UNCY has outperformed NBP by 42.4 percentage points over the past year.
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
NBP vs UNCY FAQ
Which is bigger, NovaBridge Biosciences or Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $97.77M compared with $96.28M for NovaBridge Biosciences (NBP).
Which stock has performed better over the past year, NBP or UNCY?
UNCY returned -37.96% over the past 12 months, compared with -80.38% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are NovaBridge Biosciences and Unicycive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.